Canopy Growth Narrows Losses but Stock Lags on Investor Skepticism

Operational Metrics Show Progress

Canopy Growth narrowed its net loss to $47 million in Q2 2026, down from $89 million in the prior-year quarter, according to the company's September 12 earnings release. Revenue declined 8% year-over-year to $71 million, but gross margin expanded 420 basis points to 31%, driven by cost reductions in cultivation and distribution. SG&A expenses fell by $22 million compared to the same quarter last year.

CEO David Klein attributed the margin expansion to facility consolidations completed in late 2025 and early 2026, which eliminated redundant overhead in Ontario and British Columbia. Canopy now operates three cultivation facilities in Canada. Down from seven in 2024.

Stock Performance Disconnected from Fundamentals

Canopy Growth shares closed at $1.87 on September 13, down 41% year-to-date and near the stock's 52-week low of $1.62. The disconnect between improving operations and stagnant share price reflects broader investor fatigue with Canadian licensed producers, which have collectively destroyed $30 billion in market capitalization since 2019 peaks.

Daily volume on the Nasdaq has averaged 4.2 million shares over the past month, well below the 7.8 million average in 2025. Institutional ownership dropped to 18% in Q2 2026 from 31% a year earlier, according to FactSet data.

Path to Profitability Remains Unclear

Analysts project Canopy won't achieve positive adjusted EBITDA until Q4 2027 at the earliest, contingent on U.S. market entry or international expansion. The company burned $38 million in operating cash flow in Q2 and holds $112 million in cash against $310 million in convertible debt maturing in June 2027.

Klein declined to provide specific guidance on the earnings call but said the company's "evaluating strategic partnerships" for U.S. distribution. That language echoes statements made in prior quarters without concrete follow-through. The U.S. remains federally illegal for THC products, limiting Canopy's options to CBD or hemp-derived cannabinoids.

Investor Sentiment Anchored by Dilution Risk

Canopy has issued 1.2 billion shares since 2018, diluting early shareholders by 87% on a per-share basis. The company's market capitalization sits at $740 million, less than half the $1.6 billion Constellation Brands invested between 2017 and 2019. Constellation wrote down its stake by $2.3 billion in 2023 and hasn't participated in subsequent capital raises.

The overhang of potential equity raises weighs on the stock, and analysts at Stifel and Canaccord both model additional dilution in 2027 to refinance the convertible notes. Without a clear catalyst — U.S. federal legalization, a major acquisition, or a breakout brand — retail and institutional buyers have stayed on the sidelines.

For full background on this story, see the CannIntel topic hub on Canopy Growth stock performance.

What Investors Are Watching

The next inflection point is the June 2027 debt maturity and whether Canopy can secure refinancing without issuing equity at current depressed valuations. A U.S. rescheduling decision by the DEA, expected in late 2026 or early 2027, could unlock pathways for Canadian LPs to enter American markets through partnerships or acquisitions. Until then, operational improvements alone haven't been enough to move the stock.

Klein's track record includes the BioSteel write-down and multiple restructurings. Credibility is thin. The market's waiting for proof, not promises.